Control Eczema Elidel

In order to treat those suffering with eczema, there has been a great deal of discussion in the healthcare community about the control eczema elidel (pimecrolimus) cream. So as to make both healthcare professionals along with their patients aware of the risk involved in using Elide, the FDA (Food and Drug Administration) felt it was important to issue a “public health advisory” , especially on a long term basis.

Studies on Control Eczema Elidel Cream

Control Eczema Elidel, when applied topically to the skin of eczema patients carries with it a potential risk for cancer. This information has been retrieved from three sources- first studies done on animals, second, case reports done on a specific amount of eczema patients and thirdly, due to findings on how the drug works in general. While the risk has not been established for a certainty, research is ongoing.

The FDA Recommendation on Control Eczema Elidel Cream

Patients are advised to consider the pros and cons of control eczema elidel treatment carefully. When other treatments fail to produce the desired result, the FDA recommends that Elidel only be considered as a last resort. For those who do decide to experience this method of treatment, it is highly recommended that they follow their doctor’s orders and the labels on the Elidel cream very closely and don’t ever go beyond it.

Concerning the use of control eczema elidel as a treatment for eczema, the FDA asks that physicians and patients alike to consider a number of different items. First of all, Elidel is suggested to only be used on a temporary basis for intermittent treatments of Atopic eczema and only for patients whose eczema is obstinate and refuse to respond to other treatment and/or cannot withstand other treatment methods.

Against the skin condition, control eczema elidel should be a “second-line agent” and not the first line of defense. The drug’s long-term consequences are not yet known. It cannot be emphasized enough; this drug should be used for short spurts of time but not as a continuous treatment.

Control Eczema Elidel Cream on Children

For the children who are two years or younger, elidel should never be used. Research has not yet proven what effect this drug could have on the immune system of babies or children and the FDA believes that it is not a risk worth taking until further information is known. So far, Clinical studies that have been conducted on young children had shown less than promising results.

In controlled studies babies and children under two years of age who were treated with small amounts of control eczema elidel applied topically to their skin experienced much higher rates of colds, flu, and other upper respiratory infections than those in the placebo group.

Those with a weakened immune system, in spite of of the cause should never use control eczema Elidel as its complete effects on the immune system are not known. It may in fact contribute to an even greater weakening of the immune system. This goes for both children over the age of two and adults alike.

Control Eczema Elidel cream is a “topical immunosuppressant calcineurin inhibitor” and is approved (as is the ointment Protopic) but still it must be administered with the utmost caution. In order to improve the symptoms of the eczema sufferer, use the minimum quantity that is required, never more. Several studies on animals had shown that giving high quantities of control eczema elidel to them brought about an excellent rise in the occurrence of the cancer.